Thymosin alpha Thymosin alpha is used for boosting the immune system as it increases Major Histocompatibility Complex class-1 and cytokine production, providing immunoregulatory function
Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists
While tirzepatide slows gastric emptying and reduces caloric intake through incretin receptor activation, 5-amino-1MQ works intracellularly to inhibit nicotinamide N-methyltransferase (NNMT), shifting cellular metabolism toward fat oxidation independent of appetite suppression
ALA supplementation can support glutathione production
The safety profile is strong: toxic doses sit roughly 300 to 3,750 times higher than recommended therapeutic amounts, and injection site irritation remains the most commonly reported side effect
Anxiolytic Peptide Supports stress resilience and mental clarity
